Compare Essex Property Trust, Inc. (ESS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Summit Therapeutics Inc — how do they compare? Essex Property Trust, Inc. trades at $282.11 (market cap $18.15B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Essex Property Trust, Inc. is the larger of the two by market cap, and Essex Property Trust, Inc. pays a 3.93% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ESS | SMMT | |
|---|---|---|
Market Cap | $18.15B | $12.06B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $26.98 |
52-Week Low | $239.61 | $12.55 |
Enterprise Value | $24.75B | $11.39B |
Dividend Yield | 3.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $281.27, down 0.69% on the day, with a bearish technical signal. The company reported a Q2 2026 EPS miss ($0.97 vs. $1.46 expected) but raised full-year FFO guidance. Revenue grew to $1.89B in 2025, with a strong net income margin of 35.48%, though profitability is projected to moderate in 2026. The stock is supported by a $2.59 dividend and a consensus price target of $305.86, implying potential upside.
The outlook is mixed: raised guidance and institutional buying signal confidence, but technical weakness and a high debt load pose risks. The stock offers income and growth potential if operational execution improves, yet faces headwinds from regional market softness and interest rate sensitivity.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
